Clinical Stage Drug Discovery Based on Our Proprietary Platform Technology

SMNH: Delivering Novel Chemistry Solutions for Today's Diseases

SB 9200: A Potential Breakthrough Drug for HBV

Latest News

    • DECEMBER 19, 2016

    Spring Bank and Arbutus Biopharma Announce Preclinical Collaboration in Study of Chronic Hepatitis B

    HOPKINTON, Mass., Dec. 19, 2016 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, and Arbutus Biopharma Corporation (NASDAQ:ABUS) today announced an agreement to perform collaborative preclinical studies in chronic Hepatitis B virus (HBV) involving the co-administration of Spring Bank’s SB 9200, an orally-available selective immune-modulator, and Arbutus Biopharma’s AB-423, a capsid assembly inhibitor. SB 9200 and AB-423 are each investigational compounds currently under development by the respective companies for the treatmen…

    Read more